First Signs Of Efficacy From Biogen’s Tau-Targeting Antisense Drug

After showing an impressive 60% reduction in tau levels in the brain, Biogen’s Phase I study of BIIB080 has now demonstrated early signs of an impact on cognition and daily living for Alzheimer’s patients.

Biogen

Earlier this year, Biogen presented eye-catching results from its Alzheimer’s disease candidate BIIB080, which showed it produced ”unprecedented” reductions in the tau protein – and has now followed this with small but encouraging signs that this effect also helps to slow the disease’s progress.

Data from the Phase Ib study presented in March showed 60mg and 115 mg quarterly intrathecal doses of the antisense...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D